SUPPLEMENTARY FIGURES



Supplementary Figure 1. ChIP analyses of p53 and MSK1 on the *p21* locus during p53-dependent transcription in p53-null HCT116 cells.

p53-deficient HCT116 colorectal cancer cells were treated with doxorubicin for the indicated times and ChIP analyses were performed with indicated antibodies. Error bars indicate standard deviations from three independent ChIP analyses.



35 phosphomimetic variants of MSK1

Supplementary Figure 2. Overview of MSK1 phosphomimetic mutants generation.

Five MSK1 cDNA fragments were subcloned into a pUC19-derived entry vector. Primers were designed to introduce *Bsa*l recognition sites to the 5' and 3' end of each MSK1 fragment in reverse orientation so that *Bsa*l recognition sites can be removed upon cDNA assembly and that resulting complimentary overhang sequences can be joined in a specific order. The entry vectors were used as templates for generation of phosphomimetic mutations from serine/threonine to glutamic acid by site-directed mutagenesis. For the assembly reaction, the pNTAP-*Bsa*l-LacZ vector was digested with *Bsa*l to release the *lacZ* cassette (whose 5' and 3' ends were flanked by *Bsa*l recognition sites in reverse orientation) and MSK1 entry clones were then subcloned by ligation of compatible overhangs. *B*, *Bsal* recognition site; SBP, streptavidin-binding peptide.

| | | S212E | S360E | S376, 381E | T581E | T700E | S750, 752, |
|--------|-----------------|--------|--------|---------------|--------|------------|---------------|
| | | | | | | | 758E |
| Single | | | | | | | |
| | S360E | | | | | | |
| Double | \$376, 381 F | | | | | | |
| | T581E | | | | | | |
| | T700E | | | | | | |
| | \$750, | | | | | | |
| | 752, | | | | | | |
| | 758E | | | | | | |
| | | S212E | \$360E | S376, 381E | | | |
| | S360E | | | | T581E | | |
| | | | | | | T700E | |
| | | | | | S75 | 50, 752, 7 | '58 E |
| Triple | S376, | | | | | T581E | |
| | 381E | | | | | T700E | |
| | | | | | S75 | 50, 752, 7 | '58 E |
| | T581E | | | | | T700E | |
| | | | | | 575 | 50, 752, 7 | 58E |
| | T700E | | | | | T581 | |
| | \$750, | | | | | | |
| | 752, | | | | | | |
| | 758E | | | | | | |
| | | \$360E | | S376. | | | |
| | | | | 381E | | | |
| Quad- | S212E | | | | T | 581E/T70 | 0E |
| ruple | S212E | | | | T581E/ | S750, 75 | 2. 758E |

Supplementary Figure 3. Graphical depiction of the relative histone kinase activity of 35 MSK1 phosphomimetic mutants.

H3S10 phosphorylation activities of MSK1 phosphomimetic mutants relative to MSK1* are grouped into three classes marked by white (inactive), yellow (modestly active) and red (highly active).





Supplementary Figure 4. Characterization of constitutively active (B2 fragmentcontaining) MSK1 phosphomimetic mutants in p53-dependent *p21* expression.

(a) Effects of constitutively active MSK1 phosphomimetic mutant proteins in p53-mediated *in vitro* transcription of a chromatin template. Standard p53- and p300-dependent transcription from chromatinized p53ML plasmid was performed. Reactions contained 15 ng of indicated MSK1.

(b) Effects of constitutively active MSK1 phosphomimetic mutants in endogenous p21 transcription. H1299 cells were transfected with combination of plasmids expressing p53, MKK6ca, MSK1 wild type and phosphomimetic mutants as indicated. Total RNA and cell lysates were prepared and analyzed for p21 mRNA (top panel) and for protein levels by immunoblotting with indicated antibodies (bottom panels). Error bars represent mean standard deviation from three triplicate samples. The significance of the differences in p21 expression was evaluated by Student's t-test (*n.s.*, not significant). Asterisk indicates endogenous MSK1.

SUPPLEMENTARY TABLES

Supplementary Table 1. Oligonucleotide sequences for generation of five MSK1 cDNA fragments.

| Fragments | Amino acid position | Forward Primer | Reverse Primer | 5' overhangs | 3' overhangs |
|-----------|------------------------|---|--|-----------------|-----------------|
| A | 1-227 | <i>GGTCTC</i> AAATGG AGGAAGAAGGTG GCAGCA | <i>GGTCTC</i> CCCTCTG ACAATATCTGGTGC CA | AATG | ССТС |
| В | 228-428 | <i>GGTCTC</i> AGAGGG GGAGATTCAGGA CATGA | <i>GGTCTC</i> CTTCAAAT CTAGGTCATAGTGT TGATA | GAGG | TTCA |
| С | 429-690 | <i>GGTCTC</i> TTGAAG GACAAACCCCTG GGAGAAGGT | GGTCTCTCCATCTT GTAGCCATTCATTG TACCTCA | TGAA | CCAT |
| D | 691-792 | <i>GGTCTC</i> GATGGA AGTCAGCTGTCC TCCAATGGA | <i>GGTCTC</i> CGTCTCC GGGTTATTGCTGTC GGCAGGA | ATGG | GTCT |
| E | 793-802 | <i>GGTCTC</i> GAGACG CTCTTCCAGTTCT CGGACTCAGT | <i>GGTCTC</i> GAAGCCA TAGAGCCCACCGC ATCCCCA | AGAC | CCAT |

Sequences in italic indicate Bsa1 restriction sites.

| Fragment | Mutation site | Primer name | Primer sequence |
|----------|-----------------------|------------------------------|--|
| A1 | S212E | S212E_FOR | GCATAT <i>GAG</i> TTTTGTGGAACTATTGAATACA TGG |
| | | S212E_REV | ACAAAA <i>CTC</i> ATATGCTCTTTCAGTTTCATCAG C |
| B1 | S360E | S360E_FOR | ACTTAT <i>GAG</i> CCCGCAGCCCTGCCCCAGAGT T |
| | | S360E_REV | TGCGGG <i>CTC</i> ATAAGTGGGGTCCATTTCTGT GAACT |
| B2 | S376E/S381E | S376E S381E_FOR | GAGTTTGTTGCTCCTGAGATCCTATTCAAGC GTAATGCAGCT |
| | | S376E &S381E_REV | CTCAGGAGCAACAAACTCATAGCCCTGAAA CAGCTTCTCAGA |
| C1 | T581E | T581E_FOR | CTGAAG <i>GAG</i> CCATGCTTCACCCTTCATTATG CC |
| | | T581E_REV | GCATGG <i>CTC</i> CTTCAGGGGGCTGATTATCCGG TG |
| D1 | T700E | T700E_FOR | CTGATG <i>GAG</i> CCGGATATTCTAGGATCTTCC GGA |
| | | T700E_REV | ATCCGG <i>CTC</i> CATCAGAGGATTGGAGGACAG CTG |
| D2 | S750E/S752E /S758E | S750E, S752E, & S758E_FOR | <i>GAG</i> ACC <i>GAG</i> ACCGAGACGCGCAGC <i>GAG</i> TC CAGTGAGAGTTCCCATTCTTCTT |
| | | S750E, S752E, & S758E_REV | CTCGCTGCGCGTCTCGGTCTCGGTCTCAGT CTTTTTCATTTTCTTCTTCTTAGCC |

Supplementary Table 2. Oligonucleotide sequences for introduction of glutamic acid mutation into MSK1 fragments.

Sequences in italic indicate codon sequences of glutamic acid. FOR, forward primer; REV, reverse primer.